Oxford Partial Knee System
Biomet Manufacturing Corp · Decision date Jul 13, 2026
What did the FDA decide?
FDA records P010014/S117 as a supplement to PMA P010014, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 13, 2026.
FDA approval order statement
change to the creep test pressure parameter in the package performance testing of the Oxford Partial Knee System Bearing Components
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Orthopedic
- Decision date
- Jul 13, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P010014/S117
- Regulatory pathway
- PMA supplement
- Applicant
- Biomet Manufacturing Corp
- Product code
- NRA
- Decision code
- OK30
- Decision date
- Jul 13, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, knee, femorotibial, unicompartmental, semi-constrained, metal/polymer, mobile bearing.
- Applicant
- Biomet Manufacturing Corp
- Product code
- NRA
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P010014. Subsequent supplements may change the device or its indications.
FDA decision timeline
P010014 · Original PMA
OXFORD(TM) MENISCAL UNICOMPARTMENTAL KNEE SYSTEM
P010014/S109 · Related supplement
Oxford Partial Knee System
P010014/S111 · Related supplement
Oxford Knee System
P010014/S113 · Related supplement
Oxford Partial Knee System
P010014/S114 · Related supplement
Oxford Cementless Partial Knee System
P010014/S115 · Related supplement
Oxford Partial Knee System
P010014/S116 · Related supplement
Oxford Partial Knee System
P010014/S112 · Related supplement
Oxford Partial Knee System; Cementless OxfordPartial Knee System
P010014/S117 received
Application receipt date recorded by FDA.
P010014/S117 · FDA decision
30-Day Notice
P010014/S118 · Related supplement
Oxford Partial Knee Anatomic Vivacit-E Meniscal Bearings
P010014/S119 · Related supplement
Cementless Oxford Partial Knee System
P010014/S120 · Related supplement
Oxford Partial Knee System
Timeline entries are records held by MedtechLedger for P010014. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010014
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biomet Manufacturing Corp | PMA approval | Apr 21, 2004 | FDA | |
Oxford Partial Knee SystemP010014/S109 | Biomet Manufacturing Corp | PMA supplement | Aug 7, 2025 | FDA |
Oxford Knee SystemP010014/S111 | Biomet Manufacturing Corp | PMA supplement | Aug 7, 2025 | FDA |
Oxford Partial Knee SystemP010014/S113 | Biomet Manufacturing Corp | PMA supplement | Jan 16, 2026 | FDA |
Oxford Cementless Partial Knee SystemP010014/S114 | Biomet Manufacturing Corp | PMA supplement | Mar 6, 2026 | FDA |
Oxford Partial Knee SystemP010014/S115 | Biomet Manufacturing Corp | PMA supplement | Apr 20, 2026 | FDA |
Oxford Partial Knee SystemP010014/S116 | Biomet Manufacturing Corp | PMA supplement | May 12, 2026 | FDA |
| Biomet Manufacturing Corp | PMA supplement | May 27, 2026 | FDA | |
| Biomet Manufacturing Corp | PMA supplement | Sep 1, 2026 | FDA | |
Cementless Oxford Partial Knee SystemP010014/S119 | Biomet Manufacturing Corp | PMA supplement | Oct 6, 2026 | FDA |
Oxford Partial Knee SystemP010014/S120 | Biomet Manufacturing Corp | PMA supplement | Oct 26, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biomet Manufacturing Corp
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 56 E. Bell Dr.,, P.O. Box 587, Warsaw, IN, 46581
Sources and methodology
- Original FDA record: P010014/S117
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






